Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vetprofen is a veterinary non-steroidal anti-inflammatory drug (NSAID) containing the active ingredient carprofen. It is a small molecule belonging to the propionic acid class, specifically FDA-approved for use in dogs. Its mechanism of action involves the inhibition of cyclooxygenase (COX) enzymes, which reduces the synthesis of prostaglandins responsible for pain and inflammation. Vetprofen is indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain following soft tissue and orthopedic surgeries. It is marketed by Vetoquinol USA and is available in oral caplet and flavored tablet forms in strengths of 25 mg, 75 mg, and 100 mg.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vetprofen.